Cargando…

Iodine-123-metaiodobenzylguanidine cardiac SPECT imaging in the qualification of heart failure patients for ICD implantation

Detalles Bibliográficos
Autor principal:	Teresińska, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660574/ https://www.ncbi.nlm.nih.gov/pubmed/29696486 http://dx.doi.org/10.1007/s12350-018-1288-6

Ejemplares similares

Quality and utility of [(123)I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator
por: Teresińska, Anna, et al.
Publicado: (2021)

Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?
por: Bax, Jeroen J., et al.
Publicado: (2008)

Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac (123)I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT
por: Saito, Shintaro, et al.
Publicado: (2023)

Convolutional neural network-based automatic heart segmentation and quantitation in (123)I-metaiodobenzylguanidine SPECT imaging
por: Saito, Shintaro, et al.
Publicado: (2021)

I -123 metaiodobenzylguanidine imaging for predicting ventricular arrhythmia in heart failure patients
por: Zhou, Weihua, et al.
Publicado: (2013)

Risk stratification of patients with chronic heart failure using cardiac iodine‐123 metaiodobenzylguanidine imaging: incremental prognostic value over right ventricular ejection fraction
por: Tamaki, Shunsuke, et al.
Publicado: (2015)

The Potential Role of Iodine-123 Metaiodobenzylguanidine Imaging for Identifying Sustained Ventricular Tachycardia in Patients with Cardiomyopathy
por: Klein, Thomas, et al.
Publicado: (2013)

A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging
por: Nakajima, Kenichi, et al.
Publicado: (2014)

Phantom-Based Standardization Method for (123)I-metaiodobenzylguanidine Heart-to-Mediastinum Ratio Validated by D-SPECT Versus Anger Camera
por: Yamashita, Shozo, et al.
Publicado: (2023)

Machine learning-based risk model using (123)I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure
por: Nakajima, Kenichi, et al.
Publicado: (2020)

(123)I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
por: Kitamura, Yoshiyuki, et al.
Publicado: (2021)

The potential for early diagnosis of pulmonary arterial hypertension using lung iodine-123-metaiodobenzylguanidine ((123)I-MIBG) uptake: A case report
por: Higo, Kenjuro, et al.
Publicado: (2020)

Validation of a Five-Year Prognostic Model Using (123)I-metaiodobenzylguanidine Scintigraphy in Patients with Heart Failure
por: Ishibashi, Yohei, et al.
Publicado: (2023)

Cardiac sympathetic activity in chronic heart failure: cardiac (123)I-mIBG scintigraphy to improve patient selection for ICD implantation
por: Verschure, D. O., et al.
Publicado: (2016)

Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: An (123)I-metaiodobenzylguanidine SPECT/CT study
por: Todica, Andrei, et al.
Publicado: (2018)

Variations in (123)I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation
por: Verberne, Hein J., et al.
Publicado: (2007)

Prognostic value of cardiac (123)I‐metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement
por: Kadoya, Yoshito, et al.
Publicado: (2021)

(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
por: Noordzij, Walter, et al.
Publicado: (2012)

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
por: Pitton Rissardo, Jamir, et al.
Publicado: (2023)

(123)I‐Metaiodobenzylguanidine Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms
por: Catalan, Mauro, et al.
Publicado: (2021)

Autonomic disorders and myocardial 123I-metaiodobenzylguanidine scintigraphy in Huntington’s disease
por: Assante, Roberta, et al.
Publicado: (2020)

Cardiac (123)I-metaiodobenzylguanidine Scintigraphy in a Patient with Familial Parkinsonism with Parkin Gene Mutation
por: Kim, Young-Do, et al.
Publicado: (2010)

Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio
por: Okuda, Koichi, et al.
Publicado: (2023)

The prognostic value of (123)I-mIBG SPECT cardiac imaging in heart failure patients: a systematic review
por: Pontico, Mariano, et al.
Publicado: (2021)

Evaluation of Iodine-123 and Iodine-131 SPECT activity quantification: a Monte Carlo study
por: Morphis, Michaella, et al.
Publicado: (2021)

Role of cardiac (123)I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD
por: De Vincentis, Giuseppe, et al.
Publicado: (2018)

Correction of collimator-dependent differences in the heart-to-mediastinum ratio in (123)I-metaiodobenzylguanidine cardiac sympathetic imaging: Determination of conversion equations using point-source imaging
por: Inoue, Yusuke, et al.
Publicado: (2016)

Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses
por: Lamotte, Guillaume, et al.
Publicado: (2015)

Incremental prognostic value of cardiac metaiodobenzylguanidine imaging over the co‐morbid burden in acute decompensated heart failure
por: Kayama, Kiyomi, et al.
Publicado: (2021)

HIV Dementia with a Decreased Cardiac (123)I-metaiodobenzylguanidine Uptake Masquerading as Dementia with Lewy Bodies
por: Kurihara, Masanori, et al.
Publicado: (2018)

Changes in cardiac sympathetic nerve activity on (123)I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy
por: Fukuda, Keisuke, et al.
Publicado: (2021)

Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations
por: Nakajima, Kenichi, et al.
Publicado: (2014)

Thyroid function after diagnostic (123)I-metaiodobenzylguanidine in children with neuroblastic tumors
por: Clement, Sarah C., et al.
Publicado: (2022)

Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout
por: Verberne, Hein J., et al.
Publicado: (2009)

Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of (123)I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability
por: Scholte, Arthur J. H. A., et al.
Publicado: (2010)

Complete remission of metastatic pheochromocytoma in (123)I-metaiodobenzylguanidine scintigraphy after a single session of (131)I-metaiodobenzylguanidine therapy: a case report
por: Sugino, Teruaki, et al.
Publicado: (2017)

Cardiac (123)I-mIBG Imaging in Heart Failure
por: Verschure, Derk O., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA
por: O’Day, Ken, et al.
Publicado: (2016)

Uptake Index of (123)I-metaiodobenzylguanidine Myocardial Scintigraphy for Diagnosing Lewy Body Disease
por: Kamiya, Yoshito, et al.
Publicado: (2017)

Is (123)I-metaiodobenzylguanidine heart-to-mediastinum ratio dependent on age? From Japanese Society of Nuclear Medicine normal database
por: Nakajima, Kenichi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fpg1ltahd6fv2rqt2kv76okgbl